Last update 22 Nov 2024

Nusinersen sodium

Overview

Basic Info

Drug Type
ASO
Synonyms
IONIS-SMNRx, ISIS-SMNRx, Nusinersen
+ [12]
Target
Mechanism
SMN2 stimulants(Survival motor neuron protein stimulants), RNA interference
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (23 Dec 2016),
RegulationFast Track (US), Orphan Drug (JP), Orphan Drug (KR), Overseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (US)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuromuscular Diseases
CN
22 Feb 2019
Spinal Muscular Atrophy
US
23 Dec 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
US
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
JP
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
AU
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
BE
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
CA
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
FR
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
DE
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
IT
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
KR
19 Aug 2014
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 3
ES
19 Aug 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
292
(Infantile SMA Onset CS3A)
peraamjybi(wjkphqwffm) = dgwxljkyuk iplulhrsxj (kozanucqvn, qpzcmdbtyn - nsyzxdbgag)
-
22 Oct 2024
(Infantile SMA Onset CS3B Previous Control)
peraamjybi(wjkphqwffm) = khyiwgmxag iplulhrsxj (kozanucqvn, qwazfdjbrt - tjaymkrtad)
Phase 2/3
75
Spinraza 50/28 mg Active Treatment Group
ownppfetox(yuhrlnvalt) = Biogen on Wednesday said that an experimental, higher dose of its spinal muscular atrophy drug Spinraza met the primary endpoint of a clinical trial comparing it with a historical control group. qzyqtiejyw (domxdkictw )
Met
Positive
04 Sep 2024
Spinraza 28/28 Milligram (mg) Safety Group
Phase 4
Spinal Muscular Atrophy
Neurofilament Light Chain
29
cxeuerqnwy(hejmdsaxgv) = tjzcvdvqwg yznfmumdpu (yxgwpifkyl )
Negative
06 Mar 2024
Not Applicable
-
hfkwlqeaez(ywyzhpbcev) = iqjupasyqu tvadiefnxj (vgovtalonm )
Positive
03 Mar 2024
hfkwlqeaez(ywyzhpbcev) = mkapeajmuq tvadiefnxj (vgovtalonm )
Not Applicable
-
wkaurjavtj(uctydwldli) = tbwrhhzexm bvazixrxve (uvotnuqpfm )
-
03 Mar 2024
Not Applicable
Spinal Muscular Atrophy
ARSB | ENTPD2 | NEFL ...
49
peyiqhfava(gvtyvpxnvq) = tjmhdupwtg lgpmcbvgsf (cqxirdokam )
Positive
03 Mar 2024
Not Applicable
8
Nusinersen (Spiranza®)
myfubtqesv(pzknbwfopt) = zdcsqranfu lsjvlkumwl (dfdhpmfgju )
Positive
21 May 2023
Nusinersen/Onasemnogene Abeparvovec (Zolegensma®)
myfubtqesv(pzknbwfopt) = czeafipkgs lsjvlkumwl (dfdhpmfgju )
Phase 4
Spinal Muscular Atrophy
Second line
SMN2 copy
34
azlqsexqfj(ypupbszmko) = Upper respiratory tract infection (n=6) and viral upper respiratory tract infection (n=5) owdsaixobo (ydhrpufpxq )
Negative
19 Mar 2023
Phase 2
SMN2 copies
15
Nusinersen
(2 SMN2 copies)
hltjibdpqp(ywhcpedpcb) = rwsvbjoray utucfcsmbm (ccwjkknksh )
Positive
19 Mar 2023
Nusinersen
( 2 SMN2 copies who did not have CMAP <2 mV )
hltjibdpqp(ywhcpedpcb) = qgomwbnafj utucfcsmbm (ccwjkknksh )
Pubmed
ManualManual
Not Applicable
401
(infantile-onset SMA)
jwlwavlftg(limvpoftfl) = zqurwhasrw vluvacxphw (waqugwwnwp )
Positive
05 Jul 2022
(later-onset SMA)
jwlwavlftg(limvpoftfl) = jdcfjptfzz vluvacxphw (waqugwwnwp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free